SCHEMBL1103402

SCHEMBL1103402

Cc1cccc(-c2c3ccccc3c(-c3ccccc3)c3c2cnc2ccccc23)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
HTT P42858 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
HPGD P15428 2/20 0.52
SMN1; SMN2 Q16637 4/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
NR1I3 Q14994 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 3/20 0.41
MAPK1 P28482 1/20 0.41
ABCB1 P08183 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
LMNA P02545 1/20 0.40
MAP4K4 O95819 1/20 0.39
PSMB5 P28074 1/20 0.38
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103261 0.97 ALDH1A1 (0.48) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103400 0.90 ALDH1A1 (0.47) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103483 0.90 ESR1 (0.42) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103478 0.90 ESR1 (0.42) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103523 0.89 ALDH1A1 (0.42) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103411 0.87 ALDH1A1 (0.52) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103392 0.87 ESR1 (0.41) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1105452 0.87 ESR1 (0.43) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103583 0.86 ALDH1A1 (0.42) ALDH1A1HTTNPSR1HPGDSMN1; SMN2
SCHEMBL1103399 0.86 ALDH1A1 (0.40) ALDH1A1HTTNPSR1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ALDH1A1 1015/4885HTT 4390/4885NPSR1 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.